MA

Mainz BioMed N.V.

Develops at-home diagnostic tests for the early detection of life-threatening cancers.

F

Overview

Corporate Details

ISIN(s):
NL0015000LC2 (+3 more)
LEI:
894500XWJE7LIJNYQ547
Country:
Germany
Address:
Robert-Koch-Strasse 50, 55129 Mainz
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mainz BioMed N.V. is a molecular genetics company that develops and commercializes market-ready in-vitro diagnostic (IVD) solutions for the early detection of life-threatening conditions. The company's flagship product, ColoAlert®, is a non-invasive, at-home screening test for colorectal cancer (CRC) marketed in Europe. Mainz BioMed is also advancing its product pipeline with proprietary genetic testing methods for other deadly conditions, including pancreatic cancer, to provide accessible and reliable early detection solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-08 15:00
Regulatory News Service
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel …
English 12.2 KB
2025-09-30 14:01
Regulatory News Service
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Sc…
English 12.1 KB
2025-09-23 14:01
Regulatory News Service
Mainz Biomed Announces Commercial Launch of ColoAlert in Switzerland
English 11.5 KB
2025-09-02 14:01
Regulatory News Service
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
English 11.2 KB
2025-08-13 14:01
Regulatory News Service
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert
English 11.6 KB
2025-07-23 14:01
Business and Financial Review
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for…
English 11.2 KB
2025-07-15 14:01
Earnings Release
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colore…
English 15.5 KB
2025-06-25 14:01
Regulatory News Service
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Scr…
English 11.1 KB

Automate Your Workflow. Get a real-time feed of all Mainz BioMed N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Mainz BioMed N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.